Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 13/20 | 0.72 |
| ▸ | PSEN2 | P49810 | 13/20 | 0.72 |
| ▸ | APH1B | Q8WW43 | 13/20 | 0.72 |
| ▸ | NCSTN | Q92542 | 13/20 | 0.72 |
| ▸ | APH1A | Q96BI3 | 13/20 | 0.72 |
| ▸ | PSENEN | Q9NZ42 | 13/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365377 | 0.97 | PSEN1 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6859922 | 0.97 | PSEN1 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6365133 | 0.97 | PSEN1 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15631762 | 0.95 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL551120 | 0.90 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13899693 | 0.82 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5012165 | 0.81 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL551644 | 0.80 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9976723 | 0.80 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9905344 | 0.80 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088313-A1 | SUBSTITUTED INDOLOCARBAZOLES | XEROX CORPORATION (US) | 2014-03-27 | — | — | US | disclosed |
| US-20120157689-A1 | SUBSTITUTED INDOLOCARBAZOLES | XEROX CORPORATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-8110690-B2 | Substituted indolocarbazoles | XEROX CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090036689-A1 | SUBSTITUTED INDOLOCARBAZOLES | XEROX CORPORATION (US) | 2009-02-05 | — | — | US | disclosed |
| US-7456424-B2 | Thin film transistors including indolocarbozoles | XEROX CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-7402681-B2 | Compound with indolocarbazole moieties and devices containing such compound | XEROX CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-7173140-B2 | Process to form compound with indolocarbazole moieties | XEROX CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036689-A1 | SUBSTITUTED INDOLOCARBAZOLES | HTR3C, HTR3A, AANAT | PSEN1 3162/4885PSEN2 1766/4885APH1B 4134/4885 |
| US-20120157689-A1 | SUBSTITUTED INDOLOCARBAZOLES | HTR3C, HTR3A, AANAT | PSEN1 3162/4885PSEN2 1766/4885APH1B 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.